Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
Launched by LEO PHARMA · Oct 12, 2012
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with light to moderate psoriasis vulgaris of trunk and extremities and treatment with Daivobet® Gel was planned anyway.
- • Minimum of 3 years diagnosed psoriasis vulgaris.
- Exclusion Criteria:
- • Previous therapy with Daivobet® Gel
- • Systemic therapy of psoriasis vulgaris
- • Contraindications of Daivobet® Gel in the German package insert
- • people that are incapable to give free consent
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Osnabrück, Niedersachsen, Germany
Patients applied
Trial Officials
Thomas Rosenberg, PD Dr. med.
Principal Investigator
private practise, D- 49078 Osnabrück, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials